https://www.thelancet.com/journals/langas/article/PIIS2468-1253(22)00389-2/fulltext
0
0
Neutralising antibody potency against SARS-CoV-2 wild-type and omicron BA.1 and BA.4/5 variants in patients with inflammatory bowel disease treated with infliximab and vedolizumab after three doses of COVID-19 vaccine (CLARITY IBD): an analysis of a pr - The Lancet
12/5/22 at 11:33pm
Organization
The Lancet
Authors
Details
81 words
Summarize
Health Health Conditions antibody potency anti-SARS-CoV-2 patient subgroups infliximab vedolizumab Omicron vaccine immunogenicity CLARITY IBD therapie The Lancet TNFi
Our findings underline the importance of continued SARS-CoV-2 vaccination programmes, including second-generation bivalent vaccines, especially in patient subgroups where vaccine immunogenicity and efficacy might be reduced, such as those on anti-TNF therapie…
Create an account or login to join the discussion